Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
JAN$28.90-1.15(-3.83%)BUZZ-Janus Living falls on upsized $748 mln equity raise8:51:45 AM ETMU$755.50-39.96(-5.02%)How Worried Should Investors Be About Micron Right Now?8:45:37 AM ETVST$117.05-3.25(-2.70%)Vistra Cratered by 25% This Year: One Wall Street Team Says 110% Returns Ahead for Investors8:45:31 AM ETBA$177.39+0.40(+0.23%)Updating The Non-Correlateds: Boeing And IBM Trying To Become Relevant Again8:45:00 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm Sinks 11% as Soft Profit Guidance and Handset Slump Overshadow Beat; Arm Holdings Drops 7%, Skyworks Slides 2%8:43:59 AM ETAMZN$271.16+5.13(+1.93%)Amazon: An Earnings Supercycle Is Taking Shape8:38:41 AM ETNVDA$197.20-3.09(-1.54%)Chinese AI lab Moonshot turned to Europe for Nvidia Blackwell access amid U.S. China curbs, sources tell CNBC8:34:14 AM ETHRL$22.98+0.22(+0.97%)3 Dividend Aristocrats Trading Below Their Historical Valuations8:34:12 AM ETTSM$384.84-10.78(-2.72%)TSMC's AI Opportunity Is Expanding. Here's the Question That Matters for Its Stock Price8:33:37 AM ETHD$359.57+4.13(+1.16%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.60+1.38(+0.49%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.50+3.99(+1.14%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.42+1.65(+1.32%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMCD$281.60+1.38(+0.49%)McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday8:22:06 AM ETMRNA$256.50-1.84(-0.71%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$460.24-28.54(-5.84%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$440.30+3.71(+0.85%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.66+0.67(+0.84%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$138.50+1.56(+1.14%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$755.50-39.96(-5.02%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ET

AIDX · NASDAQ

20/20 Biolabs Inc.

$0.24 +0.01 (+4.85%)

Company overview

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

Sector
Healthcare
Industry
Medical - Care Facilities
Exchange
NASDAQ
Market cap
$3.1M
Employees
14
Headquarters
Gaithersburg, MD
Website
2020biolabs.com
CEO
Jonathan Cohen
Listed
February 19, 2026
P/E
-0.22
Dividend yield
0.00%

Company financials

Revenue
$1.7M
Gross profit
$395,120
Operating income
-$5.4M
EBITDA
-$5.3M
Net income
-$6.1M
EPS
-$1.10
Total assets
$5.8M
Total debt
$618,771
Gross margin
23.68%
Net margin
-363.74%
Earnings yield
-458.33%

Price chart

0.150.540.941.331.72
AIDX 1D NASDAQ O0.24H0.27L0.22C0.23-0.01 (-2.55%)Vol770.64K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
AIDX20/20 Biolabs Inc. Press release REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026 GlobeNewswire
AIDX20/20 Biolabs Inc. Press release HEALWELL AI Announces Conference Call for Third Quarter 2026 Financial Results on November 10, 2026 Newsfile
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy GlobeNewswire
AIDX20/20 Biolabs Inc. Press release WELL Health and HEALWELL Announce Competition Bureau Has Concluded Its Merger Review and Issued a No Action Letter Newsfile
AIDX20/20 Biolabs Inc. Press release HEALWELL and WELL Health Announce Competition Bureau has Concluded Its Merger Review and Issued a No Action Letter Newsfile
AIDX20/20 Biolabs Inc. Stock news 20/20 Biolabs (NASDAQ:AIDX) and P3 Health Partners (NASDAQ:PIII) Head-To-Head Review Defense World
AIDX20/20 Biolabs Inc. Press release The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape GlobeNewswire
AIDX20/20 Biolabs Inc. Press release HEALWELL AI Named to TIME's World's Top HealthTech Companies of 2026 and Announces 12 Real-World Evidence and Clinical AI Presentations at International Conferences This Fall. Newsfile
AIDX20/20 Biolabs Inc. Stock news 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026 GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs to Host Investor Webinar on October 7, 2026 GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress GlobeNewswire
AIDX20/20 Biolabs Inc. Press release 20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 GlobeNewswire
See more
FAQ

Questions about 20/20 Biolabs Inc.

What does 20/20 Biolabs Inc. do?
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
What is AIDX's market cap?
20/20 Biolabs Inc. (AIDX) is a listed stock with a live quote. The latest market cap on this page is $3.1M.
Where is 20/20 Biolabs Inc. headquartered?
20/20 Biolabs Inc. is headquartered in Gaithersburg, MD.
How do I get AIDX news from the API?
Call GET /v1/news?tickers=AIDX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AIDX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AIDX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AIDX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs